The focus of the industry on living human beings and the strict standards it enforces provide unique considerations for business leaders. These aspects make the industry an ideal source of innovation, leading to some major breakthroughs that have boosted the yield of agricultural crops, developed biofuels, and resulted in life-saving pharmaceutical products.

When it comes to revenue-generating strategies biotech startups have a variety of options. Most choose a technology partnership or an asset-creation-and-out-licensing strategy. Technology partnering can generate more revenue and lower financial risk, while strategies for asset creation and outlicensing are able to yield much more returns. A increasing number of biotechs in the research phase employ the hybrid approach, which combines genotec-frankfurt.de both strategies.

Those who opt for an approach that is focused on product development can be successful commercially when they are able to get their pipeline to a suitable stage and then attract a major pharma partner or an investor with a large sum of money. It can be a costly venture. It is important to weigh the pros and cons of leveraging assets from outside and make proper scientific decision-making regarding domestic projects.

The “platform” model is a second alternative to generate revenue. It is less costly than product-oriented development but also involves significant risk. In this model, a biotech is the owner and develops its platform technology prior to joining with major pharma companies to develop a portfolio of drug discovery projects that focus on specific diseases (i.e., disease x within biology y). Advinus Therapeutics, among others have embraced this model.